THE CUTTING EDGE OF BIOTECHNOLOGICAL INNOVATION IN MEDICINAL MUSHROOMS

At Hifas da Terra we are committed to innovation and scientific research, offering solutions that improve people’s health and wellbeing through pre-clinical and clinical trials in which the efficacy of our products is tested and proven.

In this way we cross the biotech frontier and make our way into biopharma, researching new patentable products as well as new medical devices status for areas not currently covered by pharmacology. Our target is to contribute to a healthier and more protected society.

KEY R&D&I DATA

we allocate 62% of our profits to R&D

more than 200 MULTI-DISCIPLINARY EXPERTS WORK WITH US

We have our own large scientific team and more than 200 multidisciplinary collaborators. Some of the entities with which we collaborate include:

More than 15 active projects

We are the leading biotech in natural product research and development, with more than 15 active studies including controlled clinical trials in oncology patients, as well as quality clinical research in the area of women’s health, gut microbiota and in patients with COVID-19 and long COVID, SIBO-Irritable Bowel Syndrome, DAO deficiency and diverticular disease.

SCIENTIFIC AND BIOTECHNOLOGICAL INNOVATION

Through innovation we elaborate new processes and protocols that have a positive impact on people’s well-being. We do this by building on existing evidence from medicinal mushrooms and clinical research and introducing innovative and sustainable technological processes and smart 4.0 technologies. The result is the creation of a new model of safe and effective food supplements that answer real needs.

WE USE NEW INTELLIGENT TECHNOLOGIES AND OPTIMISE PRODUCTION PROCESSES TO OPTIMISE THE QUALITY OF OUR EXTRACTS

IWe innovate in the organic cultivation of medicinal mushrooms by introducing sustainable production in bioreactors, a pioneering system that allows us to cultivate mycelium under standardised conditions and expands the medical applications of the extracts by varying culture media, selecting specific strains oriented to results, etc. This system also allows us to more efficiently isolate active biomolecules and new ingredients that improve our nutritional supplements.

WE DEVELOP TAILOR-MADE FORMULATIONS WITH SPECIFIC CONCENTRATIONS OF ACTIVE INGREDIENTS AND PROVEN BIOLOGICAL ACTIVITY

We are laying the foundations for what we call “mycotherapy à la carte”, i.e. the formulation of novel products to address specific situations and specific genetic conditions. Currently, at Hyfas da Terra we already conduct studies to demonstrate the safety and efficacy of our products, a global standard of excellence that applies to all new projects and products.

NEW PATENTS

The know-how acquired thanks to the scientific and technological expertise of our R&D&I team opens the door to the creation of new patents based on medicinal mushrooms and their applications, whether it be in the form of food supplements or medical devices, amongst others.

QUALITY OF LIFE AND WELL-BEING

Conducting model studies and clinical trials in patients with prevalent diseases and symptoms.

SCIENTIFIC AND BIOTECHNOLOGICAL INNOVATION

Through innovation we elaborate new processes and protocols that have a positive impact on people’s well-being. We do this by building on existing evidence from medicinal mushrooms and clinical research and introducing innovative and sustainable technological processes and smart 4.0 technologies. The result is the creation of a new model of safe and effective food supplements that answer real needs.

OPTIMISING THE QUALITY OF EXTRACTS

We innovate in the organic cultivation of medicinal mushrooms by introducing sustainable production in bioreactors, a pioneering system that allows us to cultivate mycelium under standardised conditions and expands the medical applications of the extracts by varying culture media, selecting specific strains oriented to results, etc. This system also allows us to more efficiently isolate active biomolecules and new ingredients that improve our nutritional supplements.

WE DEVELOP TAILOR-MADE FORMULATIONS WITH SPECIFIC CONCENTRATIONS OF ACTIVE INGREDIENTS AND PROVEN BIOLOGICAL ACTIVITY

We are laying the foundations for what we call “mycotherapy à la carte”, i.e. the formulation of novel products to address specific situations and specific genetic conditions. Currently, at Hyfas da Terra we already conduct studies to demonstrate the safety and efficacy of our products, a global standard of excellence that applies to all new projects and products.

 

NEW PATENTS

The know-how acquired thanks to the scientific and technological expertise of our R&D&I team opens the door to the creation of new patents based on medicinal mushrooms and their applications, whether it be in the form of food supplements or medical devices, amongst others.

QUALITY OF LIFE AND WELL-BEING

Conducting model studies and clinical trials in patients with prevalent diseases and symptoms.

THERAPEUTIC AREAS OF RESEARCH

CLINICAL TRIALS 2020 – 2025

Micromarker

2018 – 2023
  • 2021
  • Randomised double-blind vs. placebo clinical trial in colorectal cancer (Mico-Digest 2.0)
  • Patients: 144
  • Medical centre: Fundación Biomédica Galicia Sur / Complejo Hospitalario Público de Ourense
Human trials and studies Related News

Microinmunomama

2020 – 2023
  • Planned start 2021
  • Randomised, double-blind, placebo-controlled clinical trial in breast cancer (Mico-Mama 2.0)
  • Patients: > 100, exact number to be determined
  • Medical centre: Fundación Biomédica Galicia Sur / Complejo Hospitalario Público Álvaro Cunqueiro in Vigo
Related News

Other R&D projects and observational studies in humans

Nutrigen 4.0

2021 – 2024
  • Implementation of Intelligent Processes for the production of nutritional supplements based on the analysis of new biosynthetic pathways in the genomes of two strains of edible mushrooms from Galicia.
Related News

Covid-19 study in residences

2020
  • Observational study in patients with SARS-COV-2 tested with PCR and/or laboratory tests compatible with active COVID-19 infection under supplementation with HdT fungal extracts.
  • Patients: 76
  • Medical centre: Centro De Asistencia Médico Geriátrico Leganés / Dr. Soler
Related News

Mico-Artro

2018
  • Effects of two mushroom extracts on symptom relief in patients with osteoarthritis: Observations in daily clinical practice.
  • Patients: 20
  • Medical centre: OAFI (International Osteoarthritis Foundation) / Dr. S. Moller
Related News

Neurofood

2018 – 2021
  • R&D project with human trial on the effects of medicinal mushrooms from Hifas da Terra on memory and cognition in healthy adults. Possible implications in cognitive decline or neurodegenerative pathologies (Alzheimer’s, Parkinson’s).
  • Patients: 40
  • Medical centre: Centro Sanitario Foltra / Dr. Devesa
Related News

FungitechOnco

2019 – 2021
  • Industrial development of the cultivation of medicinal mushroom species to attain new compounds with anticarcinogenic activity applicable in products aimed at the prevention and treatment of gastric and colorectal cancers.
Related News

Dismetasín

2018 – 2021
  • Ingredients with health properties in the industrial development of target foods to reduce the incidence of metabolic syndrome. Clinical trial on the effects of Mico-MIX in patients with metabolic syndrome.
  • Patients: 68
  • Medical centre: Complejo Hospitalario de Santiago de Compostela / Dr Felipe Casanueva
Related News

SCIENTIFIC PUBLICATIONS

2019

In Vitro Anti-proliferative and Anti-invasive Effect of Polysaccharide-rich Extracts from Trametes versicolor and Grifola frondosa in Colon Cancer Cells.

International Journal of Medical Sciences

See now

2019

Autohydrolysis of Lentinus edodes for Obtaining Extracts with Antiradical Properties.

MDPI

See now

2019

Innovative technologies for the extraction of saccharidic and phenolic fractions from Pleurotus eryngii.

LWT – Food Science and Technology, Elsevier

See now

2017

Clinical utility and safety of Ganoderma lucidum (Bio-Ganoderma) in Acute Lymphoblastic Leukaemia as a adjuvant therapy: a case report (Póster N.º 30).

Developmental Perinatal and Paediatric Pharmacology Congress

Ver más

2016

Estudio de la toxicidad producida por el tratamiento con extractos de hongos comestibles en carcinoma de colon.

III Jornada de Investigación Biomédica del Cáncer en Galicia

Ver más

2016

MALDI-TOF to compare polysaccharide profiles from commercial health supplements of different mushroom species.

 

Ver más

2015

Sequential extraction of Hericium erinaceus using green solvents.

LWT – Food Science and Technology

Ver más

2014

Improving Training Condition Assessment in Endurance Cyclists: Effects of Ganoderma lucidum and Cordyceps sinensis.

Hindawi Publishing Corporation

Ver más

Communications at conferences

See more